Inventiva is trimming its pipeline and enacting layoffs in an effort to get its lead MASH drug approved, the company ...

Leaked Pfizer Phase 1 trial shows mevrometostat plus Xtandi reduced prostate cancer progression risk by 49%. Data sparked ...

Novartis acquires Anthos' abelacimab for $925M upfront and up to $3.1B total, marking CEO Bill Meury's second major exit and ...

A federal court in Massachusetts temporarily blocked the Trump administration’s new cap on indirect cost reimbursements for ...

Novo Nordisk hit back at telehealth company Hims’ controversial Super Bowl commercial touting cheaper versions of brand-name ...

Eli Lilly is betting up to $630 million on an experimental MASH treatment from a South Korean biotech. The pharma giant ...

Twenty-two state attorneys general sued the Trump administration on Monday in a bid to halt a new cap on indirect costs for ...

Vertex chief operating officer Stuart Arbuckle plans to retire in July, the company announced Monday afternoon. He will be ...

Several brand-name drugmakers believe they will withstand any drug pricing impacts from President Donald Trump’s tariffs — ...

Boehringer Ingelheim said its experimental treatment for a chronic lung disease succeeded in a pivotal study, and it's taking ...

Roche's $8 billion InterMune acquisition, disclosed a decade ago, is now being handed to a specialty pharmaceutical company.

German pharma company Merck KGaA confirmed that it is in talks to acquire SpringWorks Therapeutics, though a deal has yet to be announced.